In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol consumption.

SURPASS-2 was an open label, 40-week, phase-3 trial which randomized patients to receive once-weekly injections of Mounjaro at a dose of 5 mg, 10 mg, or 15 mg, or Ozempic at a dose of 1 mg.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Already approved at a lower dose as Ozempic for treating diabetes, the new 2.4 mg once-weekly formulation – which will be sold as Wegovy – is the first new medicine to be approved in the US ...

Tirzepatide will be available at pharmacies in Ireland initially in doses of 2.5 mg and 5 mg, with availability of higher ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Medically reviewed by Elizabeth Barnes, RDN Berberine is a natural compound in flowering plants like barberry, coptis root, ...

Cleveland Clinic experts reveals what's behind "Ozempic face," and list the semaglutide-associated symptoms that can call for ...

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...